HCA Healthcare Appoints John W. Chidsey III to Board

By Philip Seaworth • Sunday, July 13 15:19 • Permanent Link

HCA Healthcare, Inc. has announced the appointment of John W. Chidsey, III as an independent director, effective July 15, 2025. With this addition, the company's board of directors has increased from nine to ten members. Mr. Chidsey will serve on HCA Healthcare’s audit and compliance committee, compensation committee, and patient safety and quality of care committee.

Mr. Chidsey brings a wealth of experience, having served as the global chief executive officer of Subway, as well as holding significant leadership roles at Burger King Holdings, Inc. and Cendant Corporation. He has also served on the boards of Norwegian Cruise Line Holdings Ltd, Encompass Health Corporation, Burger King Holdings, Inc. (as chairman), and Brinker International, Inc.

According to Thomas F. Frist III, chairman of the board of HCA Healthcare, Mr. Chidsey's extensive experience in leading corporate strategy at large, complex public and private companies will provide invaluable insight as a board member. Mr. Chidsey's financial, operational, and executive leadership experience and expertise are expected to complement HCA Healthcare’s commitment to the care and improvement of human life.

HCA Healthcare, based in Nashville, operates 192 hospitals and approximately 2,500 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics in 20 states and the United Kingdom. The company, founded in 1968, has created a new model for hospital care in the United States, using combined resources to strengthen hospitals, deliver patient-focused care, and improve the practice of medicine.

HCA Healthcare has conducted a number of clinical studies, including one that demonstrated that full-term delivery is healthier than early elective delivery of babies and another that identified a clinical protocol that can reduce bloodstream infections in ICU patients by 44%. The company uses its approximately 44 million annual patient encounters to advance science, improve patient care, and save lives. Following these announcements, the company's shares moved -0.59%, and are now trading at a price of $376.07. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.